课题基金 / 基金详情

Rethinking radioimmunotherapy: Radiolabeling anti-PD-L1 targeting peptides for bimodal treatment of cancer.

Rethinking radioimmunotherapy: Radiolabeling anti-PD-L1 targeting peptides for bimodal treatment of cancer.
重新思考放射免疫疗法：放射性标记抗 PD-L1 靶向肽用于癌症的双模式治疗。
批准号：
396461
负责人：
Lau Joseph
金额：
$10.93万
依托单位：
National Institutes of Health (Bethesda)
依托单位国家：
加拿大
项目类别：
Fellowship Programs
财政年份：
2018
资助国家：
加拿大
项目状态：
已结题
起止时间：
2018-11-01 至 2021-11-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=396461&lang=en
关键词：
Cancer Immunotherapy Nuclear Imaging Pd-L1 Positron Emission Tomography Radiotherapy

项目摘要

项目成果

Lau Joseph的其他基金

相似基金

相关文献

中文摘要
翻译
根据加拿大癌症统计数据，据估计，2017年全国有20.6万例癌症诊断和8.08万例癌症相关死亡。癌症对治疗产生抗药性的一个特征是它们的逃避能力
英文摘要
According to the Canadian Cancer Statistics, it was estimated that there were 206,000 cancer diagnoses and 80,800 cancer-related deaths in 2017 across the nation. One of the hallmarks of cancers that make them resistant to therapy is their ability to evad
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeting Carbonic Anhydrase IX and Hypoxia for the Diagnosis and Treatment of Aggressive Breast Cancers
Synthesis and evaluation of an 18F-labelled coumarin derivative for imaging carbonic anhydrase IX expression in cancers with Positron Emission Tomography
海外基金